@article{ce5136cf867b41c0a197da85d1a68a95,
title = "Hyperprogression upon immunotherapy: A chance for (hyper-)progress",
author = "Roch Houot and Aur{\'e}lien Marabelle and St{\'e}phane Champiat",
note = "Funding Information: R.H. received honoraria or consulting fees from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen and Celgene. A.M. has received honoraria or consulting fees from the following companies: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca / Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Roche / Genentech, Merck (MSD), Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, SOTIO, Pillar Partners and BPI. S.C. has received honoraria from Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis and Roche.",
year = "2020",
month = feb,
day = "1",
doi = "10.1016/j.ejca.2019.12.011",
language = "English",
volume = "126",
pages = "139--140",
journal = "European Journal of Cancer",
issn = "0959-8049",
}